<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02972476</url>
  </required_header>
  <id_info>
    <org_study_id>2014RC07</org_study_id>
    <secondary_id>2016-000734-21</secondary_id>
    <nct_id>NCT02972476</nct_id>
  </id_info>
  <brief_title>Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial</brief_title>
  <acronym>MUSIC</acronym>
  <official_title>Investigating the Mechanism of Inhaled Corticosteroids Associated Pneumonia by Longitudinal Characterisation of the Airway Microbiome in Patients With Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled trial to test the hypothesis that inhaled therapies for chronic&#xD;
      obstructive pulmonary disease (COPD) have differential effects on the upper airway&#xD;
      microbiome.&#xD;
&#xD;
      COPD is the third leading cause of death worldwide. Exacerbations drive disease progression&#xD;
      and worsening quality of life and therefore prevention of exacerbations has been a major goal&#xD;
      of treatment.&#xD;
&#xD;
      Patients with COPD are frequently prescribed inhaled corticosteroids (ICS) which have been&#xD;
      shown to reduce exacerbations in combination with long acting beta2-adrenoceptor agonists&#xD;
      (LABA). In recent years, all ICS preparations have been associated with a significant&#xD;
      increased risk of pneumonia in either randomised trials or observational studies leading to&#xD;
      warnings from national regulatory authorities and leading experts. This has led to a&#xD;
      re-evaluation of the role of ICS in COPD treatments. It is likely that the risk of pneumonia&#xD;
      is not equal across all ICS doses and molecules.&#xD;
&#xD;
      There is a compelling rationale for ICS having a strong effect on the upper airway&#xD;
      microbiome, and that this may be one mechanism of increased pneumonia risk with these drugs.&#xD;
      The existing literature regarding ICS and pneumonia risk are lacking; 1) there are no head to&#xD;
      head trials comparing different ICS preparations and 2) the comparator in these studies to&#xD;
      date have been long acting beta2-adrenoceptor agonists alone, whereas the most appropriate&#xD;
      comparator in current management would be combined LABA and long-acting muscarinic antagonist&#xD;
      (LAMA).&#xD;
&#xD;
      The MUSIC TRIAL is a multi-centre randomised open label controlled parallel group study with&#xD;
      four treatment arms and a total of 120 participants. Severe COPD patients currently treated&#xD;
      with inhaled corticosteroid therapy will be randomised to treatment with one of three&#xD;
      preparations of ICS in combination with LABA or the control arm of dual bronchodilator&#xD;
      therapy following a four week washout period. Participants will return monthly to determine&#xD;
      if there are changes in the microbiome in their upper airway.&#xD;
&#xD;
      This study will establish one potential mechanism for the increased susceptibility to&#xD;
      pneumonia in ICS users and assess intraclass differences in ICS molecules and the effect of&#xD;
      ICS dose on the microbiome. Demonstrating that different COPD treatments can have different&#xD;
      effects on the lung microbiome is an important step in understanding clinical differences in&#xD;
      the safety and effectiveness of different treatments for severe COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inhaled corticosteroids (ICS) are commonly prescribed for patients with chronic obstructive&#xD;
      pulmonary disease (COPD), but their role in the management of COPD is currently being&#xD;
      re-evaluated in light of new evidence and the emergence of alternative treatments. Studies&#xD;
      have shown that the use of ICS and particularly ICS combined with long acting&#xD;
      beta2-adrenoceptor agonists (LABA) in individuals with COPD reduces the frequency of COPD&#xD;
      exacerbations and improves health status and lung function compared to LABA alone or placebo.&#xD;
      The current National Institute for Care Excellence (NICE) guidelines for COPD recommend ICS&#xD;
      for patients with a forced expiratory volume in 1 second below 50% predicted, or for patients&#xD;
      with higher lung function who have persisting symptoms or exacerbations despite treatment&#xD;
      with long acting bronchodilators. Data suggests that up to 75% of patients with COPD in the&#xD;
      United Kingdom (UK) are subsequently prescribed ICS.&#xD;
&#xD;
      The daily dose of ICS utilised in COPD treatments are much higher than those used in asthma&#xD;
      treatments, with licensed daily doses being 1000 mcg fluticasone propionate (2000 mcg&#xD;
      beclomethasone dipropionate (BDP) equivalents) or 800 mcg budesonide (800 mcg BDP&#xD;
      equivalents).&#xD;
&#xD;
      Recent concerns have been expressed about the safety of ICS in COPD following several&#xD;
      randomised controlled trials of fluticasone propionate and fluticasone furoate, among others,&#xD;
      demonstrating an increase in rates of pneumonia as an adverse event. Several systematic&#xD;
      reviews and observational studies confirm an association between ICS use and risk of&#xD;
      pneumonia.&#xD;
&#xD;
      All ICS preparations have been associated with an increased risk of pneumonia in either&#xD;
      randomised trials or observational studies leading to warnings from national regulatory&#xD;
      authorities and leading experts.&#xD;
&#xD;
      It is likely however, that the risk of pneumonia is not equal across all ICS doses and&#xD;
      molecules. Research into this area is greatly limited by the lack of head to head comparisons&#xD;
      between different ICS preparations in COPD.&#xD;
&#xD;
      It is hypothesised that the anti-inflammatory and immunosuppressive effects of ICS lead to&#xD;
      increase susceptibility to colonisation of the upper respiratory tract with pathogenic&#xD;
      bacteria associated with pneumonia such as S. pneumoniae and Haemophilus influenzae. This&#xD;
      study will establish one potential mechanism for the increased susceptibility to pneumonia in&#xD;
      ICS users and assess intraclass differences in ICS molecules used in COPD and the effect of&#xD;
      ICS dose. It is known that changes in the microbiome in COPD are associated with disease&#xD;
      severity and with lung inflammation. Demonstrating that different COPD treatments can have&#xD;
      different effects on the lung microbiome is an important step in understanding clinical&#xD;
      differences in the safety and effectiveness of different treatments for severe COPD. The&#xD;
      longer term clinical objective of this study is therefore to determine whether a proportion&#xD;
      of patients with COPD might be more safely managed with either lower dose, pharmacologically&#xD;
      different ICS preparations or with LABA/LAMA therapies to reduce the risk of pneumonia.&#xD;
&#xD;
      Hypothesis Fluticasone propionate will facilitate a higher level of bacterial airway&#xD;
      colonisation by pathogens associated with pneumonia compared to budesonide or treatment&#xD;
      exclusively with bronchodilators, therefore providing a mechanistic explanation for increased&#xD;
      pneumonia risk associated with ICS.&#xD;
&#xD;
      STUDY OBJECTIVES To determine a potential mechanism of inhaled corticosteroid associated&#xD;
      pneumonia in COPD by demonstrating ICS effects on the upper (throat and nasal swabs) and&#xD;
      lower airway (sputum) microbiome.&#xD;
&#xD;
      To determine the mechanism of observed differences in pneumonia risk between fluticasone&#xD;
      propionate, and budesonide by demonstrating differential effects on the airway microbiome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction</measure>
    <time_frame>Baseline, 1, 2, and 3 months</time_frame>
    <description>To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on upper airway bacterial load from oropharyngeal swabs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction.</measure>
    <time_frame>Baseline, 1, 2, and 3 months</time_frame>
    <description>To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on lower airway bacterial load and microbiome from sputum and on upper airway in nasophyarengeal swab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction.</measure>
    <time_frame>Baseline, 1, 2, and 3 months</time_frame>
    <description>To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity using the Shannon-Wiener diversity index determined by 16S microbiome sequencing</measure>
    <time_frame>Baseline, 1, 2, and 3 months</time_frame>
    <description>To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on lower airway microbiome from sputum and on upper airway in nasopharyngeal swab. To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity using the Shannon-Wiener diversity index determined by 16S microbiome sequencing</measure>
    <time_frame>Baseline, 1, 2, and 3 months</time_frame>
    <description>To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity using the Shannon-Wiener diversity index determined by 16S microbiome sequencing</measure>
    <time_frame>Baseline, 1, 2, and 3 months</time_frame>
    <description>To compare the effects on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum of individual inhaled corticosteroids (ICS) fluticasone propionate and budesonide (pooled ICS group) compared to a dual bronchodilator based regime without ICS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of Operational Taxonomic Units of protocol defined respiratory pathogens.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on lower airway microbiome from sputum and on upper airway in nasopharyngeal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of Operational Taxonomic Units of protocol defined respiratory pathogens.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of Operational Taxonomic Units of protocol defined respiratory pathogens.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To compare the effects on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum of individual inhaled corticosteroids (ICS) fluticasone propionate and budesonide (pooled ICS) compared to a dual bronchodilator based regime without ICS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in airway microbiota bacterial species diversity measured using the Shannon Wiener diversity indexand beta diversity indices.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bacterial load of respiratory pathogens determined by quantitative polymerase chain reaction Microbiome characterisation</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To compare the impact of high and low dose inhaled corticosteroid fluticasone propionate on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bacterial load of respiratory pathogens determined by quantitative polymerase chain reaction</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To compare the impact of high and low dose inhaled corticosteroid fluticasone propionate on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers in the sputum.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To evaluate the impact of inhaled corticosteroids on airway inflammation. Comparing inhaled corticosteroids to dual bronchodilator regimes alone. Measured with neutrophil elastase, myeloperoxidase, IL-8, IL-1beta.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers in the blood.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To evaluate the impact of inhaled corticosteroids on airway and systemic inflammation. Comparing inhaled corticosteroids to dual bronchodilator regimes alone. Measued with eosinophils &amp; neutrophils, C-reactive protein, serum resistin, specific IgG antibody to bacterial pathogens.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of adverse events/serious adverse events between groups on dual bronchodilators and inhaled corticosteroids</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To evaluate the safety and tolerability of withdrawal of inhaled corticosteroids in severe Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Forced expiratory volume in 1 second</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To evaluate the safety and tolerability of withdrawal of inhaled corticosteroids in severe Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in patient self reported measures</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To evaluate the safety and tolerability of withdrawal of inhaled corticosteroids in severe Chronic Obstructive Pulmonary Disease using St. George's Respiratory Questionnaire and Chronic Obstructive Pulmonary Disease Assessment Test score</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between change in alpha and beta diversity indices and the frequency of adverse events</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>To evaluate if changes in the airway microbiota are associated with AEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of inflammatory markers before and after one month washout period.</measure>
    <time_frame>-1 months and baseline</time_frame>
    <description>To determine the impact of inhaled corticosteroids withdrawal on airway inflammation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of bacterial load before and after one month washout period.</measure>
    <time_frame>-1 months and baseline</time_frame>
    <description>To determine the impact of inhaled corticosteroids withdrawal on airway bacterial load</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of microbiome characterisation before and after one month washout period.</measure>
    <time_frame>-1 months and baseline</time_frame>
    <description>To determine the impact of inhaled corticosteroids withdrawal on airway microbiome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiota diversity determined by 16s microbiome sequencing using the Shannon Diversity index.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To provide a longitudinal characterisation of the upper and lower airway microbiome in oropharyngeal/nasopharyngeal swabs and sputum in Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Bacterial community composition determined by 16s microbiome sequencing using number of reads of protocol defined respiratory pathogens.</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To provide a longitudinal characterisation of the upper and lower airway microbiome in oropharyngeal/nasopharyngeal swabs and sputum in Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Total bacterial load using qPCR</measure>
    <time_frame>Start of decontamination period (washout) to end of decontamination period (baseline)</time_frame>
    <description>To assess the effectiveness of chlorhexidine decontamination on lower airway microbiology in sputum in Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Bacterial community composition determined by 16s microbiome sequencing</measure>
    <time_frame>Start of decontamination period (washout) to end of decontamination period (baseline)</time_frame>
    <description>To assess the effectiveness of chlorhexidine decontamination on upper and lower airway microbiology in Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Bacterial community composition determined by 16s microbiome sequencing</measure>
    <time_frame>Start of decontamination period (washout) to end of decontamination period (baseline)</time_frame>
    <description>To assess the effectiveness of chlorhexidine decontamination on upper airway microbiome in sputum in Chronic Obstructive Pulmonary Disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life- St Georges Respiratory Questionnaire</measure>
    <time_frame>Baseline, 1 and 3 months</time_frame>
    <description>To evaluate patient reported outcome measures on three different inhaled corticosteroids regimes compared to dual bronchodilator regimes using St. George's Respiratory Questionnaire and Chronic Obstructive Pulmonary Disease assessment test score</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of oropharyngeal swabs with quantitative PCR, and 16s sequencing to measure validity, responsiveness and reliability comparing inhaled corticosteroids to dual bronchodilator regimes alone</measure>
    <time_frame>Baseline, 1, 2 and 3 months</time_frame>
    <description>To compare different microbiological methods for the assessment of changes in the upper and lower airway microbiome in COPD</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>From baseline to 3 months follow-up.</time_frame>
    <description>To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of time to first exacerbation of Chronic Obstructive Pulmonary Disease</measure>
    <time_frame>From Baseline to 3 months</time_frame>
    <description>To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of exacerbations of Chronic Obstructive Pulmonary Disease</measure>
    <time_frame>Baseline, 3 months and as required, for example when an exacerbation occurs.</time_frame>
    <description>To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to next exacerbation of Chronic Obstructive Pulmonary Disease</measure>
    <time_frame>Baseline, 3 months and as required, for example when an exacerbation occurs.</time_frame>
    <description>To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1: Symbicort 400/12 &amp; Eklira Genuair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide 400mcg &amp; formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Seretide 500/50 &amp; Eklira Genuair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate 500mcg &amp; salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Seretide 250/50 &amp; Eklira Genuair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate 250mcg &amp; salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Duaklir Genuair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aclidinium bromide 340mcg &amp; formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide &amp; formoterol fumarate and Aclidinium bromide</intervention_name>
    <arm_group_label>1: Symbicort 400/12 &amp; Eklira Genuair</arm_group_label>
    <other_name>Symbicort Turbohaler and Eklira Genuair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone 500 &amp; salmeterol and Aclidinium bromide</intervention_name>
    <arm_group_label>2: Seretide 500/50 &amp; Eklira Genuair</arm_group_label>
    <other_name>Seretide Accuhaler 500/50 and Eklira Genuair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone 250 &amp; salmeterol and Aclidinium bromide</intervention_name>
    <arm_group_label>3: Seretide 250/50 &amp; Eklira Genuair</arm_group_label>
    <other_name>Seretide Accuhaler 250/50 and Eklira Genuair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide &amp; formoterol fumarate</intervention_name>
    <arm_group_label>4: Duaklir Genuair</arm_group_label>
    <other_name>Duaklir Genuair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged greater than or equal to 40 years&#xD;
&#xD;
          -  Current or ex smokers having at least a 10 pack year smoking history&#xD;
&#xD;
          -  A clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) made by a&#xD;
             physician with a post-bronchodilator forced expiratory volume 1 (FEV1)/ forced vital&#xD;
             capacity (FVC) ratio at screening of &lt;70%&#xD;
&#xD;
          -  Severe COPD according to consensus guidelines consisting of a post-bronchodilator FEV1&#xD;
             &lt;50% predicted at screening and/or a history of 2 or more exacerbations in the&#xD;
             previous year OR one hospital admission for an exacerbation of COPD in the previous&#xD;
             year (equivalent to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011&#xD;
             grade C and D)&#xD;
&#xD;
          -  Able to perform all study procedures including spirometry and questionnaires with&#xD;
             minimal assistance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Asthma (defined according to Scottish Intercollegiate Guidelines Network)&#xD;
&#xD;
          -  A primary diagnosis of bronchiectasis confirmed on high-resolution computed&#xD;
             tomography.(it is not necessary to perform a computerised tomography (CT) scan to&#xD;
             exclude this if the patient has not previously had one. Only known bronchiectasis with&#xD;
             a previous CT scan should be excluded).&#xD;
&#xD;
          -  • Antibiotics within the past 28 days, apart from oral macrolides which are permitted&#xD;
             if they have been used for at least 3 months prior to randomization&#xD;
&#xD;
          -  Oral/ nasal corticosteroids of any kind in the 28 days prior to screening visit&#xD;
&#xD;
          -  Current use of the following: roflumilast, ritonavir, itraconazole, telithromycin, or&#xD;
             ketoconazole (or other CYP3A4 inhibitors).&#xD;
&#xD;
          -  Active, or within 28 days of screening visit, oral candidiasis, actively receiving&#xD;
             dental treatment for oral infection or poor dentition.&#xD;
&#xD;
          -  Immunosuppression including current oral corticosteroids at a dose &gt;5mg for &gt;28 days.&#xD;
&#xD;
          -  Glomerular filtration rate (eGFR) below 30ml/min/1.73meter squared or requiring&#xD;
             dialysis. Last known eGFR result will be used .&#xD;
&#xD;
          -  Use of any investigational drugs within five times of the elimination half-life after&#xD;
             the last study dose or within 30 days, whichever is longer.&#xD;
&#xD;
          -  Known allergy, intolerance or contraindication to any of the study drugs&#xD;
&#xD;
          -  Galactose intolerance&#xD;
&#xD;
          -  Unstable co-morbidities (cardiovascular disease, active malignancy) which in the&#xD;
             opinion of the Investigator would make the patient unsuitable to be enrolled in the&#xD;
             study. This includes any abnormality identified on screening bloods or screening&#xD;
             electrocardiograph which in the opinion of the Investigator would make the patient&#xD;
             unsuitable for the study.&#xD;
&#xD;
          -  An exacerbation of COPD occurring during the screening to randomisation period. If&#xD;
             this occurs the patient should be withdrawn from the study and may be rescreened once&#xD;
             they have been free from corticosteroid and antibiotic treatment for 28 days. In these&#xD;
             cases patients would receive the current Participant Information Sheet and be&#xD;
             consented prior to starting the study from Visit 1.&#xD;
&#xD;
          -  Documented that the patient has never received pneumococcal polysaccharide vaccination&#xD;
&#xD;
          -  Receipt of Pneumococcal conjugate vaccine (e.g PCV-13)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) who are not practicing an acceptable method&#xD;
             of contraception (see below)&#xD;
&#xD;
        Acceptable forms of contraception:&#xD;
&#xD;
          -  combined (estrogen and progestogen containing) hormonal contraception associated with&#xD;
             inhibition of ovulation: oral, intravaginal, transdermal&#xD;
&#xD;
          -  progestogen-only hormonal contraception associated with inhibition of ovulation: oral,&#xD;
             injectable, implantable&#xD;
&#xD;
          -  intrauterine device (IUD)&#xD;
&#xD;
          -  intrauterine hormone-releasing system ( IUS)&#xD;
&#xD;
          -  bilateral tubal occlusion&#xD;
&#xD;
          -  vasectomised partner&#xD;
&#xD;
          -  sexual abstinence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Chalmers, MBChB, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospital NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Fife</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire</name>
      <address>
        <city>Wishaw</city>
        <zip>ML2 0DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 18, 2023</submitted>
    <submission_canceled>June 8, 2023</submission_canceled>
    <submitted>June 8, 2023</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02972476
org study id: 2014RC07
secondary id: 2016-000734-21
nct id: NCT02972476
lead sponsor: 
collaborator: 
collaborator: 
has dmc: No
A randomised controlled trial to test the hypothesis that inhaled therapies for chronic
      obstructive pulmonary disease (COPD) have differential effects on the upper airway
      microbiome.

      COPD is the third leading cause of death worldwide. Exacerbations drive disease progression
      and worsening quality of life and therefore prevention of exacerbations has been a major goal
      of treatment.

      Patients with COPD are frequently prescribed inhaled corticosteroids (ICS) which have been
      shown to reduce exacerbations in combination with long acting beta2-adrenoceptor agonists
      (LABA). In recent years, all ICS preparations have been associated with a significant
      increased risk of pneumonia in either randomised trials or observational studies leading to
      warnings from national regulatory authorities and leading experts. This has led to a
      re-evaluation of the role of ICS in COPD treatments. It is likely that the risk of pneumonia
      is not equal across all ICS doses and molecules.

      There is a compelling rationale for ICS having a strong effect on the upper airway
      microbiome, and that this may be one mechanism of increased pneumonia risk with these drugs.
      The existing literature regarding ICS and pneumonia risk are lacking; 1) there are no head to
      head trials comparing different ICS preparations and 2) the comparator in these studies to
      date have been long acting beta2-adrenoceptor agonists alone, whereas the most appropriate
      comparator in current management would be combined LABA and long-acting muscarinic antagonist
      (LAMA).

      The MUSIC TRIAL is a multi-centre randomised open label controlled parallel group study with
      four treatment arms and a total of 120 participants. Severe COPD patients currently treated
      with inhaled corticosteroid therapy will be randomised to treatment with one of three
      preparations of ICS in combination with LABA or the control arm of dual bronchodilator
      therapy following a four week washout period. Participants will return monthly to determine
      if there are changes in the microbiome in their upper airway.

      This study will establish one potential mechanism for the increased susceptibility to
      pneumonia in ICS users and assess intraclass differences in ICS molecules and the effect of
      ICS dose on the microbiome. Demonstrating that different COPD treatments can have different
      effects on the lung microbiome is an important step in understanding clinical differences in
      the safety and effectiveness of different treatments for severe COPD.
Inhaled corticosteroids (ICS) are commonly prescribed for patients with chronic obstructive
      pulmonary disease (COPD), but their role in the management of COPD is currently being
      re-evaluated in light of new evidence and the emergence of alternative treatments. Studies
      have shown that the use of ICS and particularly ICS combined with long acting
      beta2-adrenoceptor agonists (LABA) in individuals with COPD reduces the frequency of COPD
      exacerbations and improves health status and lung function compared to LABA alone or placebo.
      The current National Institute for Care Excellence (NICE) guidelines for COPD recommend ICS
      for patients with a forced expiratory volume in 1 second below 50% predicted, or for patients
      with higher lung function who have persisting symptoms or exacerbations despite treatment
      with long acting bronchodilators. Data suggests that up to 75% of patients with COPD in the
      United Kingdom (UK) are subsequently prescribed ICS.

      The daily dose of ICS utilised in COPD treatments are much higher than those used in asthma
      treatments, with licensed daily doses being 1000 mcg fluticasone propionate (2000 mcg
      beclomethasone dipropionate (BDP) equivalents) or 800 mcg budesonide (800 mcg BDP
      equivalents).

      Recent concerns have been expressed about the safety of ICS in COPD following several
      randomised controlled trials of fluticasone propionate and fluticasone furoate, among others,
      demonstrating an increase in rates of pneumonia as an adverse event. Several systematic
      reviews and observational studies confirm an association between ICS use and risk of
      pneumonia.

      All ICS preparations have been associated with an increased risk of pneumonia in either
      randomised trials or observational studies leading to warnings from national regulatory
      authorities and leading experts.

      It is likely however, that the risk of pneumonia is not equal across all ICS doses and
      molecules. Research into this area is greatly limited by the lack of head to head comparisons
      between different ICS preparations in COPD.

      It is hypothesised that the anti-inflammatory and immunosuppressive effects of ICS lead to
      increase susceptibility to colonisation of the upper respiratory tract with pathogenic
      bacteria associated with pneumonia such as S. pneumoniae and Haemophilus influenzae. This
      study will establish one potential mechanism for the increased susceptibility to pneumonia in
      ICS users and assess intraclass differences in ICS molecules used in COPD and the effect of
      ICS dose. It is known that changes in the microbiome in COPD are associated with disease
      severity and with lung inflammation. Demonstrating that different COPD treatments can have
      different effects on the lung microbiome is an important step in understanding clinical
      differences in the safety and effectiveness of different treatments for severe COPD. The
      longer term clinical objective of this study is therefore to determine whether a proportion
      of patients with COPD might be more safely managed with either lower dose, pharmacologically
      different ICS preparations or with LABA/LAMA therapies to reduce the risk of pneumonia.

      Hypothesis Fluticasone propionate will facilitate a higher level of bacterial airway
      colonisation by pathogens associated with pneumonia compared to budesonide or treatment
      exclusively with bronchodilators, therefore providing a mechanistic explanation for increased
      pneumonia risk associated with ICS.

      STUDY OBJECTIVES To determine a potential mechanism of inhaled corticosteroid associated
      pneumonia in COPD by demonstrating ICS effects on the upper (throat and nasal swabs) and
      lower airway (sputum) microbiome.

      To determine the mechanism of observed differences in pneumonia risk between fluticasone
      propionate, and budesonide by demonstrating differential effects on the airway microbiome.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Basic Science
masking: None (Open Label)
measure: Change in bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction
time frame: Baseline, 1, 2, and 3 months
description: To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on upper airway bacterial load from oropharyngeal swabs.
measure: Change in bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction.
time frame: Baseline, 1, 2, and 3 months
description: To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on lower airway bacterial load and microbiome from sputum and on upper airway in nasophyarengeal swab.
measure: Change in bacterial load of total respiratory pathogens determined by quantitative polymerase chain reaction.
time frame: Baseline, 1, 2, and 3 months
description: To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.
measure: Microbiota diversity using the Shannon-Wiener diversity index determined by 16S microbiome sequencing
time frame: Baseline, 1, 2, and 3 months
description: To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on lower airway microbiome from sputum and on upper airway in nasopharyngeal swab. To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.
measure: Microbiota diversity using the Shannon-Wiener diversity index determined by 16S microbiome sequencing
time frame: Baseline, 1, 2, and 3 months
description: To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.
measure: Microbiota diversity using the Shannon-Wiener diversity index determined by 16S microbiome sequencing
time frame: Baseline, 1, 2, and 3 months
description: To compare the effects on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum of individual inhaled corticosteroids (ICS) fluticasone propionate and budesonide (pooled ICS group) compared to a dual bronchodilator based regime without ICS
measure: Change in number of Operational Taxonomic Units of protocol defined respiratory pathogens.
time frame: Baseline, 1, 2 and 3 months
description: To determine the effects of the inhaled corticosteroids fluticasone propionate/salmeterol 500/50 mcg vs budesonide/formoterol 400/12 mcg on lower airway microbiome from sputum and on upper airway in nasopharyngeal swab
measure: Change in number of Operational Taxonomic Units of protocol defined respiratory pathogens.
time frame: Baseline, 1, 2 and 3 months
description: To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.
measure: Change in number of Operational Taxonomic Units of protocol defined respiratory pathogens.
time frame: Baseline, 1, 2 and 3 months
description: To compare the effects on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum of individual inhaled corticosteroids (ICS) fluticasone propionate and budesonide (pooled ICS) compared to a dual bronchodilator based regime without ICS
measure: Change in airway microbiota bacterial species diversity measured using the Shannon Wiener diversity indexand beta diversity indices.
time frame: Baseline, 1, 2 and 3 months
description: To compare the effects of fluticasone/salmeterol 250/50mcg vs budesonide/formoterol 400/12 mcg on upper and lower airway microbiome in oropharyngeal/nasopharyngeal and sputum samples.
measure: Change in bacterial load of respiratory pathogens determined by quantitative polymerase chain reaction Microbiome characterisation
time frame: Baseline, 1, 2 and 3 months
description: To compare the impact of high and low dose inhaled corticosteroid fluticasone propionate on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum
measure: Change in bacterial load of respiratory pathogens determined by quantitative polymerase chain reaction
time frame: Baseline, 1, 2 and 3 months
description: To compare the impact of high and low dose inhaled corticosteroid fluticasone propionate on the upper and lower airway microbiome in oropharyngeal, nasopharyngeal swabs and sputum
measure: Changes in inflammatory markers in the sputum.
time frame: Baseline, 1, 2 and 3 months
description: To evaluate the impact of inhaled corticosteroids on airway inflammation. Comparing inhaled corticosteroids to dual bronchodilator regimes alone. Measured with neutrophil elastase, myeloperoxidase, IL-8, IL-1beta.
measure: Changes in inflammatory markers in the blood.
time frame: Baseline, 1, 2 and 3 months
description: To evaluate the impact of inhaled corticosteroids on airway and systemic inflammation. Comparing inhaled corticosteroids to dual bronchodilator regimes alone. Measued with eosinophils & neutrophils, C-reactive protein, serum resistin, specific IgG antibody to bacterial pathogens.
measure: Comparison of adverse events/serious adverse events between groups on dual bronchodilators and inhaled corticosteroids
time frame: Baseline, 1, 2 and 3 months
description: To evaluate the safety and tolerability of withdrawal of inhaled corticosteroids in severe Chronic Obstructive Pulmonary Disease
measure: Change in Forced expiratory volume in 1 second
time frame: Baseline, 1, 2 and 3 months
description: To evaluate the safety and tolerability of withdrawal of inhaled corticosteroids in severe Chronic Obstructive Pulmonary Disease
measure: Change in patient self reported measures
time frame: Baseline, 1, 2 and 3 months
description: To evaluate the safety and tolerability of withdrawal of inhaled corticosteroids in severe Chronic Obstructive Pulmonary Disease using St. George's Respiratory Questionnaire and Chronic Obstructive Pulmonary Disease Assessment Test score
measure: Correlation between change in alpha and beta diversity indices and the frequency of adverse events
time frame: Baseline, 3 months
description: To evaluate if changes in the airway microbiota are associated with AEs
measure: Comparison of inflammatory markers before and after one month washout period.
time frame: -1 months and baseline
description: To determine the impact of inhaled corticosteroids withdrawal on airway inflammation.
measure: Comparison of bacterial load before and after one month washout period.
time frame: -1 months and baseline
description: To determine the impact of inhaled corticosteroids withdrawal on airway bacterial load
measure: Comparison of microbiome characterisation before and after one month washout period.
time frame: -1 months and baseline
description: To determine the impact of inhaled corticosteroids withdrawal on airway microbiome.
measure: Microbiota diversity determined by 16s microbiome sequencing using the Shannon Diversity index.
time frame: Baseline, 1, 2 and 3 months
description: To provide a longitudinal characterisation of the upper and lower airway microbiome in oropharyngeal/nasopharyngeal swabs and sputum in Chronic Obstructive Pulmonary Disease
measure: Bacterial community composition determined by 16s microbiome sequencing using number of reads of protocol defined respiratory pathogens.
time frame: Baseline, 1, 2 and 3 months
description: To provide a longitudinal characterisation of the upper and lower airway microbiome in oropharyngeal/nasopharyngeal swabs and sputum in Chronic Obstructive Pulmonary Disease
measure: Total bacterial load using qPCR
time frame: Start of decontamination period (washout) to end of decontamination period (baseline)
description: To assess the effectiveness of chlorhexidine decontamination on lower airway microbiology in sputum in Chronic Obstructive Pulmonary Disease
measure: Bacterial community composition determined by 16s microbiome sequencing
time frame: Start of decontamination period (washout) to end of decontamination period (baseline)
description: To assess the effectiveness of chlorhexidine decontamination on upper and lower airway microbiology in Chronic Obstructive Pulmonary Disease
measure: Bacterial community composition determined by 16s microbiome sequencing
time frame: Start of decontamination period (washout) to end of decontamination period (baseline)
description: To assess the effectiveness of chlorhexidine decontamination on upper airway microbiome in sputum in Chronic Obstructive Pulmonary Disease
measure: Quality of life- St Georges Respiratory Questionnaire
time frame: Baseline, 1 and 3 months
description: To evaluate patient reported outcome measures on three different inhaled corticosteroids regimes compared to dual bronchodilator regimes using St. George's Respiratory Questionnaire and Chronic Obstructive Pulmonary Disease assessment test score
measure: Comparison of oropharyngeal swabs with quantitative PCR, and 16s sequencing to measure validity, responsiveness and reliability comparing inhaled corticosteroids to dual bronchodilator regimes alone
time frame: Baseline, 1, 2 and 3 months
description: To compare different microbiological methods for the assessment of changes in the upper and lower airway microbiome in COPD
measure: Change in FEV1
time frame: From baseline to 3 months follow-up.
description: To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points
measure: Comparison of time to first exacerbation of Chronic Obstructive Pulmonary Disease
time frame: From Baseline to 3 months
description: To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points
measure: Number of exacerbations of Chronic Obstructive Pulmonary Disease
time frame: Baseline, 3 months and as required, for example when an exacerbation occurs.
description: To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points
measure: Time to next exacerbation of Chronic Obstructive Pulmonary Disease
time frame: Baseline, 3 months and as required, for example when an exacerbation occurs.
description: To evaluate if changes in the airway microbiome or airway inflammatory profiles are associated with efficacy or safety end-points
arm group label: 1: Symbicort 400/12 & Eklira Genuair
arm group type: Active Comparator
description: Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
arm group label: 2: Seretide 500/50 & Eklira Genuair
arm group type: Active Comparator
description: Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
arm group label: 3: Seretide 250/50 & Eklira Genuair
arm group type: Active Comparator
description: Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
arm group label: 4: Duaklir Genuair
arm group type: Active Comparator
description: Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
intervention type: Drug
intervention name: Budesonide & formoterol fumarate and Aclidinium bromide
arm group label: 1: Symbicort 400/12 & Eklira Genuair
other name: Symbicort Turbohaler and Eklira Genuair
intervention type: Drug
intervention name: Fluticasone 500 & salmeterol and Aclidinium bromide
arm group label: 2: Seretide 500/50 & Eklira Genuair
other name: Seretide Accuhaler 500/50 and Eklira Genuair
intervention type: Drug
intervention name: Fluticasone 250 & salmeterol and Aclidinium bromide
arm group label: 3: Seretide 250/50 & Eklira Genuair
other name: Seretide Accuhaler 250/50 and Eklira Genuair
intervention type: Drug
intervention name: Aclidinium bromide & formoterol fumarate
arm group label: 4: Duaklir Genuair
other name: Duaklir Genuair
criteria: 
gender: All
minimum age: 40 Years
maximum age: N/A
healthy volunteers: No
last name: James Chalmers, MBChB, MRCP
role: Principal Investigator
affiliation: University of Dundee
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Lung Diseases
mesh term: Lung Diseases, Obstructive
mesh term: Pulmonary Disease, Chronic Obstructive
mesh term: Fluticasone
mesh term: Xhance
mesh term: Budesonide
mesh term: Bromides
mesh term: Formoterol Fumarate
mesh term: Salmeterol Xinafoate
mesh term: Fluticasone-Salmeterol Drug Combination
sharing ipd: Undecided
submitted: May 18, 2023
submission canceled: June 8, 2023
submitted: June 8, 2023